Company Overview and News

 
Infosys Q2 results: 5 things to watch out for

13h livemint
New Delhi: The heartening development at Infosys Ltd is that 10 months into his role as chief executive officer, Salil Satish Parekh is firmly in control of India’s second largest information technology (IT) services firm. But this aside, the mood at the company is edgy. Attrition has remained high even as senior management departures continue to rock the firm. Many within, and outside, Infosys are not sure if the company is benefiting from the uptick in demand for IT services.
532540 INFY TCS TTNQY

2
TCS to start disclosing revenue from digital business

18h livemint
Mumbai: Tata Consultancy Services Ltd (TCS) will start outlining the business from some of the individual components it now calls digital, a top company executive said. Beginning next quarter, India’s largest information technology (IT) outsourcing company will also disclose revenue from cloud computing, data analytics and TCS Interactive, reflecting its confidence in monetizing business from these newer technologies.
IBM 532540 ACN TCS TTNQY

1
Three of top-10 firms lose Rs 1 lakh cr in m-cap; TCS hit hard

2018-10-14 thehindubusinessline
Three of the 10 most valued Indian companies together witnessed an erosion of Rs 1,07,026.12 crore in market capitalisation last week, with IT major Tata Consultancy Services (TCS) taking the biggest knock.
500325 KMBKY RELIANCE HINDUNILVR TTNQY MRZUY 532500 532540 HDB MARUTI 500180 RIGD KOTAKBANK 500696 HDFCBANK TCS 500247 RLNIY SBAZ

1
Three of top-10 cos lose Rs 1 lakh crore in m-cap; TCS takes biggest knock of Rs 85,330.17 crore

2018-10-14 financialexpress
Three of the 10 most valued Indian companies together witnessed an erosion of Rs 1,07,026.12 crore in market capitalisation last week, with IT major TCS taking the biggest knock. Tata Consultancy Services (TCS), ITC and Infosys suffered a decline in their valuation for the week ended Friday, whereas RIL, HDFC Bank, Hindustan Unilever Ltd (HUL), HDFC, SBI, Kotak Mahindra Bank and Maruti Suzuki India finished with gains.
500325 KMBKY RELIANCE HINDUNILVR TTNQY MRZUY 532500 532540 HDB MARUTI 500180 RIGD KOTAKBANK 500696 HDFCBANK TCS 500247 RLNIY SBAZ

 
TCS to recruit 28,000 from campuses, its highest in three years

2018-10-13 financialexpress
Tata Consultancy Services (TCS) is going on a hiring spree and is slated to employ 28,000 freshers from college campuses. This is the company’s highest hiring number in the last three years and signals a strong demand for its services. In the last two years, TCS hired 20,000 freshers but this year’s number outscores it by 40%.
532540 TCS TTNQY

 
TCS to recruit 28,000 from campuses, its highest in three years

2018-10-13 financialexpress
Tata Consultancy Services (TCS) is going on a hiring spree and is slated to employ 28,000 freshers from college campuses. This is the company’s highest hiring number in the last three years and signals a strong demand for its services. In the last two years, TCS hired 20,000 freshers but this year’s number outscores it by 40%.
532540 TCS TTNQY

4
Big gainers of the week - HPCL, Yes Bank, Bajaj Finance, RIL top the charts

2018-10-13 moneycontrol
Bulls had almost everything going their way on Friday, as benchmarks shrugged off weakness coming in from global markets and saw one of the biggest one-day gains since May 2016. For the week ended on October 12, 2018, both Sensex and the Nifty gained 1-1.5 percent.
IOC 500325 RELIANCE HCTHY TTNQY 505200 532540 RIGD 532281 BJJQY 500570 ZEEL TATAMOTORS EICHERMOT RLNIY 500034 YESBANK ECQRY 532648 YYBKY 530965 BAJFINANCE ZEEEY HCLTECH 505537 TCS HINDPETRO 500104 TTM

 
Tata Consultancy Services Q2 net rises 22.6% on strong revenue growth

2018-10-12 freepressjournal.in
Mumbai: Tata Consultancy Services (TCS), the country’s largest software exporter, on Thursday reported a 22.6 per cent jump in consolidated net profit at Rs 7,901 crore in the July-September 2018 quarter, buoyed by strong demand for digital services. TCS had posted a net profit of Rs 6,446 crore in the same period last fiscal, the company said in a statement.
532540 TCS TTNQY

 
TCS falls nearly 3 per cent

2018-10-12 thehindubusinessline
Software major Tata Consultancy Services Ltd (TCS) shares fall as much as 2.9 per cent to Rs 1,922.35, its lowest level since July 11
532540 TCS TTNQY

 
Share market LIVE updates: Sensex, Nifty to remain cautious ahead of macro-data release; HUL, Yes Bank in focus

2018-10-12 financialexpress
Share market live: Sensex and Nifty — the benchmark indices of the Indian stock market — are likely to start on a tepid note on Friday on caution ahead of major macro-economic data release later during the day. SGX Nifty futures were trading 57.50 points or 0.56% higher at 10,337 points on the Singapore Exchange during early morning deals in today, indicating a positive start for the NSE Nifty 50 index.
YESBANK 513010 SPXCF KTKBANK HINDUNILVR 532648 YYBKY TTNQY S68 532652 SPXCY 532540 TATASPONGE 500696 TCS

 
Q2FY19: TCS turns in good show, weak rupee helps

2018-10-11 financialexpress
On the back of winning customers for its digital offerings and benefiting from the slide in rupee against the dollar, the country’s biggest software exporter, Tata Consultancy Services (TCS) on Thursday posted a strong set of numbers for the July-September quarter.
532540 TCS TTNQY

 
Tata Consultancy Services Limited - Date of payment of dividend

2018-10-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532540 TCS TTNQY

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...